Clinical Trial

This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.

Study acronym: NERAM-PF
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a trial designed to evaluate the combination of nerandomilast with mycophenolate across a wide variety of pulmonary fibrosis subtypes, with the aim of providing clinicians with assurance that this is an appropriate therapeutic combination.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-01.
Trial Details
NCT Number NCT07570888
Lead Sponsor University of British Columbia
Collaborators: Boehringer Ingelheim
Conditions Pulmonary Fibrosis, Interstitial Lung Disease (ILD)
Enrollment 120 participants
Start Date 2026-06
Primary Completion 2027-06 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-11